| Cardiovascular outcomes in patients with primary aldosteronism after treatment. | |
| | |
MedLine Citation:
|
PMID: 18195199 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Experimental and human studies demonstrate that long-term exposure to elevated aldosterone levels results in cardiac and vascular damage. METHODS: We investigated long-term cardiovascular outcomes in patients with primary aldosteronism after surgical or medical treatment. Fifty-four patients with or without evidence of adrenal adenomas were prospectively followed up for a mean of 7.4 years after treatment with adrenalectomy or spironolactone. Patients with primary aldosteronism were compared with patients with essential hypertension and were treated to reach a blood pressure of less than 140/90 mm Hg. The main outcome measure was a combined cardiovascular end point comprising myocardial infarction, stroke, any type of revascularization procedure, and sustained arrhythmias. RESULTS: At baseline, the prevalence of cardiovascular events was greater in primary aldosteronism (35%) than in essential hypertension (11%) (odds ratio, 4.61; 95% confidence interval, 2.38-8.95; P< .001), with odds ratios of 4.93, 4.36, and 2.80 for sustained arrhythmias, cerebrovascular events, and coronary heart disease, respectively. Blood pressure during follow-up was comparable in the primary aldosteronism and essential hypertension groups. Ten patients in the primary aldosteronism group and 19 in the essential hypertension group reached the primary end point (P= .85). Cox analysis indicated that older age and longer duration of hypertension were factors independently associated with the cardiovascular end point. Cardiovascular outcome was comparable in patients with aldosteronism treated with adrenalectomy vs aldosterone antagonists (P= .71). CONCLUSION: Primary aldosteronism is associated with a cardiovascular complication rate out of proportion to blood pressure levels that benefits substantially from surgical and medical treatment in the long term. |
| | |
Authors:
|
Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi |
Related Documents
:
|
17634629 - Selected zinc metabolism parameters in women with arterial hypotension. 18090669 - Aldosterone and progression of renal disease. 18212439 - Effect of age on hypertension: analysis of over 4,800 referred hypertensive patients. 19352049 - Endothelial dysfunction is related to aldosterone excess and raised blood pressure. 7034789 - The effect of biofeedback-assisted relaxation training on blood pressure and selected b... 17490489 - Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflum... 22327669 - Analysis of intracranial pressure time series using wavelets (haar basis functions). 12660419 - Microalbuminuria is closely related to impaired arterial elasticity in untreated patien... 12435299 - The inhibition of pulmonary vessel remodeling by carbon monoxide system in rats with ch... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Archives of internal medicine Volume: 168 ISSN: 0003-9926 ISO Abbreviation: Arch. Intern. Med. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2008-01-15 Completed Date: 2008-02-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372440 Medline TA: Arch Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 80-5 Citation Subset: AIM; IM |
Affiliation:
|
Hypertension and Cardiovascular Unit, Division of Internal Medicine, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenalectomy Adult Aged Aldosterone / blood* Aldosterone Antagonists / therapeutic use Cardiovascular Diseases / blood, etiology* Female Follow-Up Studies Humans Hyperaldosteronism / complications*, therapy Hypertension / complications Male Middle Aged Prospective Studies Spironolactone / therapeutic use Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 52-01-7/Spironolactone; 52-39-1/Aldosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonar...
Next Document: Effectiveness of antiretroviral treatment in a South African program: a cohort study.